Literature DB >> 22918234

The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division.

Jennifer McQueen1, Dewald van Dyk, Barry Young, Chris Loewen, Vivien Measday.   

Abstract

The glycogen synthase kinase-3 homolog, Mck1, has been implicated in many cellular functions, from sporulation to calcium stress response in budding yeast. Here, we report a novel function for Mck1 in the inhibition of Clb2-Cdk1 activity post nuclear division. Clb2-Cdk1, the major mitotic cyclin-Cdk complex in yeast, accumulates before anaphase and must be inhibited in telophase for cells to exit mitosis and enter into the next cell cycle. We show that the mck1Δ mutant is highly sensitive to increased Clb2-Cdk1 activity caused either by overexpression of Clb2 or the Cdk1-activating phosphatase Mih1. Deletion of the Cdk1 inhibitory kinase, SWE1, in combination with a mck1Δ mutant results in a synthetic growth defect, suggesting that Mck1 and Swe1 function in parallel pathways to inhibit Clb2-Cdk1. We find that mck1Δ strains have a delay in mitotic exit as well as elevated levels of Clb2-Cdk1 activity post-nuclear division. Using a co-immunoprecipitation assay, we identify a physical interaction between Mck1 and both Clb2 and Mih1. Finally, we demonstrate that phosphorylation of purified Clb2 by Cdk1 is inhibited by catalytically active Mck1 but not catalytically inactive Mck1 in vitro. We propose that Mck1 inhibits the activity of Clb2-Cdk1 via interaction with Clb2. The mammalian glycogen synthase kinase-3 homolog has been implicated in cyclin inhibition, suggesting a conserved cell cycle function for both yeast and mammalian glycogen synthase kinases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918234      PMCID: PMC3466553          DOI: 10.4161/cc.21731

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  73 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

2.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.

Authors:  Markus Welcker; Jeffrey Singer; Keith R Loeb; Jonathan Grim; Andrew Bloecher; Mark Gurien-West; Bruce E Clurman; James M Roberts
Journal:  Mol Cell       Date:  2003-08       Impact factor: 17.970

3.  Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement.

Authors:  G Draetta; D Beach
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

4.  Fission yeast p13 blocks mitotic activation and tyrosine dephosphorylation of the Xenopus cdc2 protein kinase.

Authors:  W G Dunphy; J W Newport
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

5.  Control of the yeast cell cycle is associated with assembly/disassembly of the Cdc28 protein kinase complex.

Authors:  C Wittenberg; S I Reed
Journal:  Cell       Date:  1988-09-23       Impact factor: 41.582

6.  Conservation of mechanisms controlling entry into mitosis: budding yeast wee1 delays entry into mitosis and is required for cell size control.

Authors:  Stacy L Harvey; Douglas R Kellogg
Journal:  Curr Biol       Date:  2003-02-18       Impact factor: 10.834

7.  Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle.

Authors:  J Gautier; T Matsukawa; P Nurse; J Maller
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

8.  GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs.

Authors:  Zoe Hilioti; Deirdre A Gallagher; Shalini T Low-Nam; Priya Ramaswamy; Pawel Gajer; Tami J Kingsbury; Christine J Birchwood; Andre Levchenko; Kyle W Cunningham
Journal:  Genes Dev       Date:  2003-12-30       Impact factor: 11.361

9.  cdc25+ functions as an inducer in the mitotic control of fission yeast.

Authors:  P Russell; P Nurse
Journal:  Cell       Date:  1986-04-11       Impact factor: 41.582

10.  Conservation of mitotic controls in fission and budding yeasts.

Authors:  P Russell; S Moreno; S I Reed
Journal:  Cell       Date:  1989-04-21       Impact factor: 41.582

View more
  7 in total

1.  Coupling of RNA polymerase III assembly to cell cycle progression in Saccharomyces cerevisiae.

Authors:  Marta Płonka; Donata Wawrzycka; Robert Wysocki; Magdalena Boguta; Małgorzata Cieśla
Journal:  Cell Cycle       Date:  2019-02-13       Impact factor: 4.534

2.  Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.

Authors:  F Zassadowski; K Pokorna; N Ferre; F Guidez; L Llopis; O Chourbagi; M Chopin; J Poupon; P Fenaux; R Ann Padua; M Pla; C Chomienne; B Cassinat
Journal:  Leukemia       Date:  2015-06-25       Impact factor: 11.528

3.  Fgk3 glycogen synthase kinase is important for development, pathogenesis, and stress responses in Fusarium graminearum.

Authors:  Jun Qin; Guanghui Wang; Cong Jiang; Jin-Rong Xu; Chenfang Wang
Journal:  Sci Rep       Date:  2015-02-23       Impact factor: 4.379

4.  The Yeast GSK-3 Homologue Mck1 Is a Key Controller of Quiescence Entry and Chronological Lifespan.

Authors:  Zhenzhen Quan; Lu Cao; Yingzhi Tang; Yanchun Yan; Stephen G Oliver; Nianshu Zhang
Journal:  PLoS Genet       Date:  2015-06-23       Impact factor: 5.917

5.  Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes.

Authors:  Mengjiao Wang; Liqing Chen; Wei Huang; Mingji Jin; Qiming Wang; Zhonggao Gao; Zhehu Jin
Journal:  Int J Nanomedicine       Date:  2019-02-21

Review 6.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  J A McCubrey; L S Steelman; F E Bertrand; N M Davis; S L Abrams; G Montalto; A B D'Assoro; M Libra; F Nicoletti; R Maestro; J Basecke; L Cocco; M Cervello; A M Martelli
Journal:  Leukemia       Date:  2013-06-19       Impact factor: 11.528

Review 7.  GSK-3 as potential target for therapeutic intervention in cancer.

Authors:  James A McCubrey; Linda S Steelman; Fred E Bertrand; Nicole M Davis; Melissa Sokolosky; Steve L Abrams; Giuseppe Montalto; Antonino B D'Assoro; Massimo Libra; Ferdinando Nicoletti; Roberta Maestro; Jorg Basecke; Dariusz Rakus; Agnieszka Gizak; Zoya N Demidenko; Lucio Cocco; Alberto M Martelli; Melchiorre Cervello
Journal:  Oncotarget       Date:  2014-05-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.